Chronic Hepatitis

Top Story

Baraclude safely reduces HBV DNA among children, adolescents

February 8, 2016

In a randomized phase 3 study, children and adolescents with chronic hepatitis B virus infection treated with Baraclude showed reduced infection compared with children treated with placebo, according to published findings.

Researchers randomly assigned 180 treatment-naive children and adolescents to a regimen of Baraclude (entecavir, Bristol-Myers Squibb; n = 120) or placebo (n = 60) for a duration of 48 weeks. The primary endpoint of the study was hepatitis B e antigen (HBeAg) seroconversion and reduced HBV DNA levels (less than 50 IU/mL) at 48 weeks. Follow-up was through 96 weeks.

In the Journals

Olysio/Sovaldi yield high SVR post-liver transplant

February 5, 2016
In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with hepatitis C virus…

ENYO Pharma obtains license for receptor to potentially treat HBV

February 5, 2016
ENYO Pharma announced it has entered a patent licensing agreement with Inserm Transfert and other necessary parties and obtained a license to a key patent for it to use…

Lawsuit against Gilead alleges tenofovir patent manipulation

February 2, 2016
AIDS Healthcare Foundation recently filed a federal lawsuit against Gilead Sciences accusing the company of patent system manipulation for various formulations of its…
CME

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Meeting News CoverageVideo

Antiviral regimens produced high SVR rates in liver transplant recipients with recurring HCV

November 12, 2014
More »
Featured
In the Journals

Baraclude safely reduces HBV DNA among children, adolescents

February 8, 2016
In a randomized phase 3 study, children and adolescents with chronic hepatitis B virus infection treated with Baraclude showed reduced infection…
In the Journals

Olysio/Sovaldi yield high SVR post-liver transplant

February 5, 2016
In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with…

ENYO Pharma obtains license for receptor to potentially treat HBV

February 5, 2016
ENYO Pharma announced it has entered a patent licensing agreement with Inserm Transfert and other necessary parties and obtained a license to a key…

Lawsuit against Gilead alleges tenofovir patent manipulation

February 2, 2016
AIDS Healthcare Foundation recently filed a federal lawsuit against Gilead Sciences accusing the company of patent system manipulation for various…
In the Journals

HBV cases increase among IDUs in Appalachian states

February 1, 2016
The incidence of hepatitis B virus infection appears to have increased in three Appalachian states from 2006 to 2013, especially among injection drug…
In the Journals

Booster vaccine against HBV not needed, researchers find

February 1, 2016
A majority of Alaska natives showed signs of protection against hepatitis B virus infection 30 years after receiving a primary vaccination series…
Breaking News

FDA approves Zepatier for HCV genotypes 1, 4

January 29, 2016
Merck announced the FDA has approved Zepatier for the treatment of adult patients with chronic hepatitis C virus genotype 1 and 4 infection, with or…

European Commission amends Daklinza label to include various patient populations

January 28, 2016
Bristol-Myers Squibb Company announced the European Commission has expanded the drug label of Daklinza and it is now approved for use in combination…
In the Journals

HBV may lead to second primary HCC in breast cancer patients

January 22, 2016
In a retrospective study, researchers found that Chinese patients with breast cancer and hepatitis, more specifically hepatitis B virus infection…

Medicines Patent Pool administers sub-licenses for generic production of Daklinza

January 21, 2016
The Medicines Patent Pool announced it has administered sub-licenses to multiple generic companies to produce and sell Daklinza, an antiviral for the…
More Headlines »
morganatic-roan morganatic-roan